Acquisition will expand DI’s coverage in TexasAny speculation that PSS World Medical’s radiology distribution subsidiary, Diagnostic Imaging, had fallen off its steady diet of acquisitions was put to rest last month. Diagnostic Imaging
Acquisition will expand DIs coverage in Texas
Any speculation that PSS World Medicals radiology distribution subsidiary, Diagnostic Imaging, had fallen off its steady diet of acquisitions was put to rest last month. Diagnostic Imaging announced on Aug. 31 that it has signed a definitive agreement to acquire the shares of independent imaging distributor Gilbert X-Ray of Dallas. DI will pay cash for Gilbert stock, pending approval by Gilbert shareholders.
The acquisition signals DIs continuing effort to expand its reach nationwide. Before signing the agreement, Jacksonville, FL-based Diagnostic Imaging had little coverage in Texas. Once the deal is closed, Gilbert will contribute five Texas branch locations to DIs operations, for a total of 32 across the country, according to Kirk Zambetti, CEO of the Diagnostic Imaging division. DIs four existing sites serving Texas will be incorporated into Gilbert locations.
Gilbert has an incredible market share in Texas, and Texas is a critical marketplace for us from a geographical standpoint, Zambetti said. Our primary focus is to be coast-to-coast, to be the first national distribution company focused on local needs, and were doing that by acquiring key regional or local distributors. Gilbert is one of the very best regional distributors in the country.
The agreement may indicate that PSS World Medical has recovered from an acquisition slowdown it experienced following the purchase of Gulf South Medical Supply of Jackson, MS, in December 1997. PSS Worlds stock fell about 40% following the deal after revelations surfaced regarding differences in the interpretation of accounting principles between the two firms (SCAN 8/5/98). PSS World was required to renegotiate some of its acquisition deals that were based on the pooling of stock interests, according to Zambetti.
The fact that DI was able to resume its acquisition pace reflects the continuing opportunity for consolidation in the distributor market. Regional distributors have had difficulty standing as independent entities, due to a lack of access to national contracts, according to R.F. Sanford, Gilberts president. The company had decided to sell in order to survive in a competitive market.
(As an independent distributor), you have no choice of customers unless you have national contracts and are part of a national organization, Sanford said.
DI hopes the deal with Gilbert will strengthen its position as an imaging equipment distributor. In the last year, the subsidiary has focused on acquiring companies like General X-Ray of St. Louis, S & W X-Ray of Rochester, NY, and MIS of Little Rock, AR, all entities strong in imaging equipment distribution.
There will be no personnel changes as a result of the Gilbert acquisition, according to Zambetti. Gilbert posts annual revenues of roughly $80 million and represents companies such as Trex Medical and OEC Medical Systems. DI executives expect the transaction to be completed late this month.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.